Leaflet NEODOLPASSE 0.30mg/0.12mg/ml 0.3mg / 0.12mg / ml solution for infusion

Indicated for: pain and inflammation

Route of administration: infusion

Substance: diclofenac + orfenadrin citrate (nonsteroidal anti-inflammatory drug + analgesic and antipyretic)

ATC: M01AB55 (Musculo-skeletal system | Antiinflammatory and antirheumatic products, non-steroids | Acetic acid derivatives and related substances)

Precautions:
Glaucoma warning
Glaucoma warning

Use caution if you have glaucoma or increased eye pressure.

Anticholinergic effects
Anticholinergic effects

May cause dry mouth, constipation, urinary retention, or blurred vision.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Nephrotoxicity
Nephrotoxicity

This medicine may affect the kidneys.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Elderly warning
Elderly warning

Older people may have an increased risk of side effects.

Bleeding risk
Bleeding risk

This medicine may increase the risk of bleeding.

Drowsiness / sedation
Drowsiness / sedation

This medicine may cause drowsiness or reduced alertness.

Ulcer / gastrointestinal bleeding
Ulcer / gastrointestinal bleeding

This medicine may increase the risk of ulcer or gastrointestinal bleeding.

The combination of diclofenac and orphenadrine citrate is used for the treatment of pain and inflammation associated with musculoskeletal conditions. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID), while orphenadrine has muscle relaxant properties.

The medication is administered orally or via injection, as directed by a doctor. It is important to follow the recommended dose to minimize the risk of side effects.

Side effects may include nausea, abdominal pain, dizziness, or drowsiness. In rare cases, severe allergic reactions, gastric ulcers, or renal failure may occur.

This combination is not recommended for patients with active gastric ulcers, severe renal impairment, or hypersensitivity to any of the components.

General data about NEODOLPASSE 0.30mg/0.12mg/ml 0.3mg / 0.12mg / ml

  • Substance: diclofenac + orfenadrin citrate
  • Date of latest medicines list: 01-10-2019
  • Product code: W60619003
  • Concentration: 0.3mg / 0.12mg / ml
  • Pharmaceutical form: solution for infusion
  • Quantity: 10
  • Product type: Original
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.